MCID: NTR004
MIFTS: 63

Neutropenia

Categories: Blood diseases, Bone diseases, Cancer diseases, Endocrine diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neutropenia

MalaCards integrated aliases for Neutropenia:

Name: Neutropenia 12 29 54 6 43 15 37 71
Leukopenia 71

Classifications:



External Ids:

Disease Ontology 12 DOID:1227
ICD9CM 34 288.0 288.00
MeSH 43 D009503
SNOMED-CT 67 72885007
ICD10 32 D70 D70.9
UMLS 71 C0023530 C0027947

Summaries for Neutropenia

MalaCards based summary : Neutropenia, also known as leukopenia, is related to poikiloderma with neutropenia and neutropenia, severe congenital, 3, autosomal recessive. An important gene associated with Neutropenia is VPS13B (Vacuolar Protein Sorting 13 Homolog B), and among its related pathways/superpathways are JAK-STAT signaling pathway (KEGG) and Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Aztreonam and Methylprednisolone hemisuccinate have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and neutrophil, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Neutropenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood.... more...

Related Diseases for Neutropenia

Diseases in the Neutropenia family:

Neutropenia, Chronic Familial Neutropenia, Severe Congenital, 1, Autosomal Dominant
Neutropenia, Severe Congenital, 3, Autosomal Recessive Neutropenia, Severe Congenital, 4, Autosomal Recessive
Neutropenia, Severe Congenital, 2, Autosomal Dominant Neutropenia, Severe Congenital, 5, Autosomal Recessive
Neutropenia, Severe Congenital, 6, Autosomal Recessive Neutropenia, Severe Congenital, 7, Autosomal Recessive
Neutropenia, Severe Congenital, 8, Autosomal Dominant Severe Congenital Neutropenia
Elane-Related Neutropenia Severe Congenital Neutropenia Autosomal Dominant
Acquired Neutropenia Autosomal Recessive Severe Congenital Neutropenia

Diseases related to Neutropenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 949)
# Related Disease Score Top Affiliating Genes
1 poikiloderma with neutropenia 35.1 USB1 JAGN1 G6PC3
2 neutropenia, severe congenital, 3, autosomal recessive 34.6 IL3 HAX1 ELANE CSF3R CSF3 CSF2
3 idiopathic neutropenia 34.5 GFI1 CSF3R
4 severe congenital neutropenia autosomal dominant 34.4 GFI1 ELANE
5 severe congenital neutropenia 34.3 WAS VPS45 JAGN1 IL3 HAX1 GFI1
6 autosomal recessive severe congenital neutropenia 34.3 HAX1 G6PC3 ELANE CSF3R
7 cyclic neutropenia 34.2 USB1 TAZ SLC37A4 JAGN1 IL3 HAX1
8 felty syndrome 33.9 IL3 ELANE CSF3 CSF2
9 whim syndrome 33.5 HAX1 G6PC3 CSF3
10 shwachman-diamond syndrome 1 33.2 HAX1 G6PC3 ELANE CSF3R CSF3
11 leukemia, acute lymphoblastic 32.5 TPMT IL3 CSF3R CSF3 CSF2
12 granulocytopenia 31.9 IL3 CSF3 CSF2
13 thiopurines, poor metabolism of, 1 31.9 UGT1A1 TPMT
14 bacterial infectious disease 31.8 IL3 ELANE CSF3 CSF2
15 mucositis 31.5 IL3 CSF3 CSF2
16 thrombocytopenia 31.4 WAS TOP1 IL3 CSF3 CSF2
17 aspergillosis 31.4 ELANE CSF3 CSF2
18 leukemia, acute myeloid 31.3 TOP1 IL3 GFI1 ELANE CSF3R CSF3
19 lymphoma, hodgkin, classic 31.2 IL3 CSF3 CSF2
20 myelodysplastic syndrome 31.2 TOP1 IL3 HAX1 GFI1 CSF3R CSF3
21 large granular lymphocyte leukemia 31.0 CSF3 CSF2
22 aplastic anemia 30.8 TPMT IL3 CSF3R CSF3 CSF2
23 pancytopenia 30.8 TPMT IL3 G6PC3 CSF3 CSF2
24 gastroenteritis 30.7 IL3 CSF3 CSF2
25 mucormycosis 30.7 CSF3 CSF2
26 myelofibrosis 30.7 VPS45 IL3 CSF3R CSF3 CD177
27 leukemia, chronic myeloid 30.6 IL3 ELANE CSF3R CSF3 CSF2 CD177
28 refractory anemia 30.5 IL3 CSF3
29 capillary leak syndrome 30.5 ELANE CSF3 CSF2
30 chronic myelomonocytic leukemia 30.3 TOP1 CSF3R CSF3 CSF2
31 irinotecan toxicity 30.3 UGT1A1 TOP1
32 thrombocytosis 30.3 IL3 CSF3 CSF2 CD177
33 polycythemia vera 30.3 IL3 CSF3 CSF2 CD177
34 acute promyelocytic leukemia 30.2 IL3 ELANE CSF3R CSF3 CSF2
35 retinitis pigmentosa and erythrocytic microcytosis 30.2 IL3 CSF3
36 hematologic cancer 30.1 TOP1 IL3 CSF3R CSF3 CSF2
37 myeloproliferative neoplasm 30.0 IL3 CSF3R CSF3 CSF2 CD177
38 hemorrhagic cystitis 29.7 TOP1 CSF3
39 neutropenia, nonimmune chronic idiopathic, of adults 12.6
40 neutropenia, severe congenital, x-linked 12.6
41 neutropenia, severe congenital, 5, autosomal recessive 12.6
42 neutropenia, severe congenital, 1, autosomal dominant 12.6
43 neutropenia, severe congenital, 7, autosomal recessive 12.6
44 neutropenia, severe congenital, 4, autosomal recessive 12.6
45 neutropenia, severe congenital, 2, autosomal dominant 12.6
46 neutropenia, severe congenital, 6, autosomal recessive 12.5
47 neutropenia, severe congenital, 8, autosomal dominant 12.5
48 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 12.5
49 transient neonatal neutropenia 12.4
50 neutropenia, chronic familial 12.3

Comorbidity relations with Neutropenia via Phenotypic Disease Network (PDN): (show all 45)


Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Cystitis Acute Kidney Failure
Acute Leukemia Agammaglobulinemia, X-Linked
Anemia, Autoimmune Hemolytic Bladder Cancer
Bronchitis Colorectal Cancer
Decubitus Ulcer Deficiency Anemia
Esophageal Cancer Esophageal Candidiasis
Esophagitis Felty Syndrome
Female Breast Cancer Gastric Cancer
Heart Disease Hepatic Encephalopathy
Hydronephrosis Hypersplenism
Hypothyroidism Immune Deficiency Disease
Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome 1 Intestinal Obstruction
Iron Deficiency Anemia Leukemia, Chronic Lymphocytic
Main Bronchus Cancer Megakaryocytic Leukemia
Oral Candidiasis Ovarian Cancer
Paralytic Ileus Plasma Cell Neoplasm
Pneumocystosis Portal Hypertension
Postinflammatory Pulmonary Fibrosis Primary Thrombocytopenia
Protein-Energy Malnutrition Pulmonary Fibrosis and/or Bone Marrow Failure, Telomere-Related, 2
Respiratory Failure Retinitis Pigmentosa and Erythrocytic Microcytosis
Rheumatoid Arthritis Sideroblastic Anemia
Systemic Lupus Erythematosus

Graphical network of the top 20 diseases related to Neutropenia:



Diseases related to Neutropenia

Symptoms & Phenotypes for Neutropenia

GenomeRNAi Phenotypes related to Neutropenia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 10.02 USB1
2 Decreased viability GR00381-A-1 10.02 JAGN1 USB1
3 Decreased viability GR00402-S-2 10.02 CD177 CLPB CSF2 CSF3 CSF3R ELANE
4 no effect GR00402-S-1 9.62 CD177 CLPB CSF2 CSF3 CSF3R ELANE

MGI Mouse Phenotypes related to Neutropenia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CD177 CSF2 CSF3 CSF3R ELANE G6PC3
2 immune system MP:0005387 9.36 CD177 CSF2 CSF3 CSF3R ELANE G6PC3

Drugs & Therapeutics for Neutropenia

Drugs for Neutropenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 656)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aztreonam Approved Phase 4 78110-38-0 5362041 5742832
2
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
3
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
4
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
5 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Lumefantrine Approved Phase 4 82186-77-4 6437380
8
Artemether Approved Phase 4 71963-77-4 119380 68911
9
Teicoplanin Approved, Investigational Phase 4 61036-62-2
10
Ceftazidime Approved Phase 4 72558-82-8, 78439-06-2 5481173
11
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
12
Azathioprine Approved Phase 4 446-86-6 2265
13
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
14
acetic acid Approved Phase 4 64-19-7 176
15
Sodium citrate Approved, Investigational Phase 4 68-04-2
16
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
17
Doripenem Approved, Investigational Phase 4 148016-81-3 73303
18
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
19
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
20
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
21
Promethazine Approved, Investigational Phase 4 60-87-7 4927
22
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
23
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
24
Polyestradiol phosphate Approved Phase 4 28014-46-2
25
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
26
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
27
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
28
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
29
Sucralfate Approved Phase 4 54182-58-0
30 Brodalumab Approved, Investigational Phase 4 1174395-19-7
31
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
32
Acetaminophen Approved Phase 4 103-90-2 1983
33
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
34
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
35
Cefpirome Approved Phase 4 84957-29-9 5479539
36
Piperacillin Approved Phase 4 66258-76-2 43672
37
Tazobactam Approved Phase 4 89786-04-9 123630
38
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 64778 441130
39
Nicotine Approved Phase 4 54-11-5 942 89594
40
Radium Ra 223 dichloride Approved, Investigational Phase 4 444811-40-9
41
Abatacept Approved Phase 4 332348-12-6 10237
42
Sotalol Approved Phase 4 959-24-0, 3930-20-9 5253
43
Hydroxyurea Approved Phase 4 127-07-1 3657
44
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
45
Ofloxacin Approved Phase 4 82419-36-1 4583
46
Ixazomib Approved, Investigational Phase 4 1072833-77-2
47 Daratumumab Approved Phase 4 945721-28-8
48
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
49
Caspofungin Approved Phase 4 162808-62-0, 179463-17-3 468682 2826718
50
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283

Interventional clinical trials:

(show top 50) (show all 1083)
# Name Status NCT ID Phase Drugs
1 Optimal Timing and Duration of Daily G-CSF With Adjuvant TAC Chemotherapy in Node-positive Breast Cancer;Multicenter, Randomized, Open Label, Clinically IV Phase Unknown status NCT01571518 Phase 4 late leukostim;early leukostim
2 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
3 Efficacy and Safety in Micafungin Sodium for Prophylaxis Against Invasive Fungal Disease During Neutropenia in Pediatric & Adolescent Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT01135589 Phase 4 Micafungin
4 A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer Unknown status NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
5 PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia Unknown status NCT02996617 Phase 4 rhG-CSF regimen;Pegylated rhG-CSF regimen
6 G-CSF (Filgrastim) or Pegfilgrastim Secondary Prophylaxis In The Adjuvant Chemotherapy Of Early Breast Cancer Unknown status NCT00030758 Phase 4
7 Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia Unknown status NCT02463747 Phase 4 Piperacillin/tazobactam;Ceftazidim;Meropenem;Vancomycin
8 Validation of Central Venous (Port A Cath®) Blood Draws for Ciprofloxacin Pharmacokinetic Research in Patients Under Treatment for Childhood Cancer Unknown status NCT02967341 Phase 4
9 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis Unknown status NCT03380793 Phase 4 morinidazole
10 Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis. Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
11 An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease Unknown status NCT03391440 Phase 4 morinidazole
12 The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
13 Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau. Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
14 Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients Completed NCT00454272 Phase 4 Teicoplanin;Vancomycin
15 Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Following Administration by 4-hour Infusion and Bolus Injection. Completed NCT02213783 Phase 4 Imipenem;Imipenem
16 A Randomized, Open Label, Multicenter Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis as an Adjunct to Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer Completed NCT00277160 Phase 4 Neulasta (pegfilgrastim)
17 A Multicenter, Open-label, Phase 4 Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy Completed NCT00125723 Phase 4
18 A Multi-center, Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805205 Phase 4 PEG-rhG-CSF
19 Randomized Open Label Clinical Trial Directed to Optimize the Duration of Empirical Antimicrobial Therapy in Haematologic Patients With Febrile Neutropenia Completed NCT01581333 Phase 4 Empirical antimicrobial treatment discontinuation;Standard empirical antimicrobial treatment discontinuation
20 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
21 Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With Fever of Unknown Origin: a Randomized Multicenter Non-inferiority Trial. Completed NCT02149329 Phase 4 Discontinuation of imipenem-cilastatin or meropenem
22 A Multi Centre Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (REaCT-G2) Completed NCT02816164 Phase 4 Neupogen
23 A Phase IV Clinical Trial of Patients With Solid Tumours Receiving Granocyte 34 (Granulocyte Colony Stimulating Factor (G-CSF)) as Primary Prophylaxis for Chemotherapy-induced Neutropenia, in a Taxotere (Docetaxel) Based Regimen Completed NCT01107756 Phase 4 LENOGRASTIM (GRANOGYTE 34)
24 A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context. Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
25 Tobramycin én Gang Daglig Mot Tre Ganger Daglig, Gitt Med Benzylpenicillin, Til Pasienter Med nøytropen Feber Completed NCT00257790 Phase 4 Tobramycin once a day
26 Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia Completed NCT02173262 Phase 4 G-CSF;Ciprofloxacin
27 Citrate- Versus Acetate-Based Dialysate in Bicarbonate Haemodialysis: Consequences on Haemodynamics, Coagulation, Acid-Base Status and Electrolytes Completed NCT00718289 Phase 4
28 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
29 Pharmacokinetic/Pharmacodynamic Study of Doripenem in Febrile Neutropenic Patients With Possible Bacterial Infection Completed NCT01401010 Phase 4 Doripenem;doripenem
30 ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment. Completed NCT00386802 Phase 4 Antifungal drug. VORICONAZOL. (VFEND®)
31 Pharmacokinetics of Mycophenolate Mofetil Alone and in Combination With Valganciclovir in Renal and Heart Transplant Recipients Completed NCT00189150 Phase 4 Mycophenolate mofetil;Valganciclovir
32 The Multi-center, Open-label,Randomized Comparison Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy Completed NCT02805153 Phase 4 PEG-rhG-CSF;rhG-CSF
33 Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever in Pediatric Acute Leukemia: Review of Temperature and Absolute Neutrophil Completed NCT04187755 Phase 4 Ceftazidime Injection;Cefepime Injection
34 Health Economic Evaluation of Rapid Detection of Bacteraemia and Fungemia by Real Time PCR for Cases of Febrile Neutropenia, Suspicion of Endocarditis and Severe Sepsis in Intensive Care Units Completed NCT00709358 Phase 4
35 Evaluate the Safety of Combination of Orectalip® (Oxaliplatin), Fluorouracil and Leucovorin as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer Completed NCT02284529 Phase 4 Orectalip
36 Safety of Cotrimoxazole in HIV- and HAART-exposed Infants in Botswana Completed NCT01086878 Phase 4 cotrimoxazole
37 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
38 Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients Completed NCT01114165 Phase 4
39 A Phase 4 Study of the Pharmacokinetics of Oral Posaconazole (SCH 56592) Among Patients With Compromised Gastrointestinal Function and at High Risk for Invasive Fungal Infection Completed NCT00686543 Phase 4 Posaconazole
40 Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial Completed NCT01232504 Phase 4 rhGM-CSF group;rhG-CSF+rhGM-CSF group;rhG-CSF group
41 PETHEMA-LAM99:Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Completed NCT00464217 Phase 4 ARA-C;Idarubicin;Leucomax
42 Comparison of a Tacrolimus/Sirolimus/Prednisone Regimen Versus Tacrolimus/Azathioprine/Prednisone Immunosuppressive Regimen in Lung Transplantation Completed NCT00321906 Phase 4 azathioprine;sirolimus
43 Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL) Completed NCT02782845 Phase 4 Chemotherapy;Immunochemotherapy;Pegfilgrastim
44 Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
45 Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients Completed NCT00969462 Phase 4 Doxorubicin
46 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
47 A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab Completed NCT01734382 Phase 4 Tocilizumab
48 Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc® (Mayne) Regardless of Food With Sporanox® (Janssen) Under Fed Conditions Completed NCT02621905 Phase 4 Sporanox;Lozanoc
49 A Ramdomized Double Blined Placebo Controlled Oral Zinc Therapy for the Prevention of Mucositis in Patients Undergoing High Dose Chemotherapy With Stem Cell Support Completed NCT00449592 Phase 4 Zinc;Placebo
50 A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia: a Randomized Prospective Study Completed NCT00702871 Phase 4 Ranitidine;Sucralfate

Search NIH Clinical Center for Neutropenia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Ciprofloxacin
Filgrastim
FILGRASTIM-SNDZ
Immunoglobulins, Intravenous
Itraconazole
pegfilgrastim
sargramostim

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Neutropenia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: neutropenia

Genetic Tests for Neutropenia

Genetic tests related to Neutropenia:

# Genetic test Affiliating Genes
1 Neutropenia 29

Anatomical Context for Neutropenia

MalaCards organs/tissues related to Neutropenia:

40
Lung, Breast, Neutrophil, Bone, Myeloid, Bone Marrow, Prostate

Publications for Neutropenia

Articles related to Neutropenia:

(show top 50) (show all 39685)
# Title Authors PMID Year
1
Review article: optimizing SVR and management of the haematological side effects of peginterferon/ribavirin antiviral therapy for HCV - the role of epoetin, G-CSF and novel agents. 54 61
20175767 2010
2
Granulocyte colony-stimulating factor in toxic epidermal necrolysis (TEN) and Chelsea & Westminster TEN management protocol [corrected]. 54 61
19912214 2010
3
Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. 54 61
20066544 2010
4
Circadian rhythm of neutrophil counts and granulocyte macrophage-colony stimulating factor (GM-CSF) under clozapine treatment: a case report. 54 61
19396726 2010
5
Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications? 54 61
20136357 2010
6
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer. 54 61
19786849 2010
7
Genetic insights into congenital neutropenia. 54 61
19440858 2010
8
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. 54 61
19297346 2010
9
Which role for rituximab in hairy cell leukemia? Reflections on six cases. 54 61
20051682 2010
10
Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. 54 61
20021291 2010
11
A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. 54 61
20068078 2010
12
Granulocyte colony-stimulating factor receptor: stimulating granulopoiesis and much more. 54 61
19699815 2009
13
Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1. 54 61
19608554 2009
14
An outbreak of Crimean-Congo hemorrhagic fever in western Anatolia, Turkey. 54 61
19409826 2009
15
Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. 54 61
19556318 2009
16
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence. 54 61
19916175 2009
17
Prospective study of Chikungunya virus acute infection in the Island of La Réunion during the 2005-2006 outbreak. 54 61
19893613 2009
18
G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. 54 61
19794089 2009
19
Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. 54 61
19696793 2009
20
Prevention of febrile neutropenia: use of granulocyte colony-stimulating factors. 54 61
19756005 2009
21
A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. 54 61
19770418 2009
22
SBDS expression and localization at the mitotic spindle in human myeloid progenitors. 54 61
19759903 2009
23
A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. 54 61
19457938 2009
24
Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. 54 61
19446318 2009
25
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. 54 61
19223932 2009
26
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. 54 61
19513514 2009
27
[Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI]. 54 61
19620808 2009
28
[Allelic variants of TPMT and the risk of leucopenia and neutropenia in patients treated for acute leukaemia]. 54 61
20081263 2009
29
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan. 54 61
19604089 2009
30
Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. 54 61
19682195 2009
31
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. 54 61
19707503 2009
32
Association of genetic polymorphisms with interferon-induced haematologic adverse effects in chronic hepatitis C patients. 54 61
19200137 2009
33
Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. 54 61
19438482 2009
34
XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. 54 61
19404210 2009
35
Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. 54 61
19435433 2009
36
Complement factors C3a and C5a have distinct hemodynamic effects in the rat. 54 61
19285573 2009
37
A novel mutation in the G4.5 (TAZ) gene in a Greek patient with Barth syndrome. 54 61
19261493 2009
38
Ela2 mutations and clinical manifestations in familial congenital neutropenia. 54 61
19415009 2009
39
Neutropenia in congenital nephrotic syndrome of the Finnish type: role of urinary ceruloplasmin loss. 54 61
19423745 2009
40
UGT1A1*28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. 54 61
19450125 2009
41
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases. 54 61
19151787 2009
42
Cardiolipin and monolysocardiolipin analysis in fibroblasts, lymphocytes, and tissues using high-performance liquid chromatography-mass spectrometry as a diagnostic test for Barth syndrome. 54 61
19454236 2009
43
Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). 54 61
19242368 2009
44
UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. 54 61
19390945 2009
45
[Autoimmune thrombocytopenia, neutropenia and hemolysis]. 54 61
19225748 2009
46
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. 54 61
19347726 2009
47
Shwachman-Diamond syndrome neutrophils have altered chemoattractant-induced F-actin polymerization and polarization characteristics. 54 61
19211642 2009
48
Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. 54 61
18685564 2009
49
A Case of Neonatal Neutropenia Due to Anti-Fc Gamma Receptor IIIb Isoantibodies Treated with Recombinant Human Granulocyte Colony Stimulating Factor. 54 61
19730745 2009
50
Medium adsorbance fraction of reticulocyte and myeloperoxidase index may individuate a patient subset with a low risk of chemotherapy-related neutropenia. 54 61
19082461 2009

Variations for Neutropenia

ClinVar genetic disease variations for Neutropenia:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 VPS13B NM_017890.4(VPS13B):c.4620del (p.Ser1541fs)deletion Pathogenic 374163 rs1057518939 8:100523652-100523652 8:99511424-99511424
2 subset of 47 genes: TBX1 GRCh37/hg19 22q11.21(chr22:18894835-21505417)copy number loss Pathogenic 523274 22:18894835-21505417
3 VPS13B NM_017890.4(VPS13B):c.11314C>T (p.Gln3772Ter)SNV Pathogenic/Likely pathogenic 56635 rs386834061 8:100880540-100880540 8:99868312-99868312
4 SLC37A4 NM_001164277.1(SLC37A4):c.81T>A (p.Asn27Lys)SNV Uncertain significance 68290 rs193302889 11:118899999-118899999 11:119029289-119029289
5 46;XY;t(16;20)(q23.1;p11.22)Translocation Uncertain significance 267924
6 46;XX;inv(2)(q13q14.2)inversion Uncertain significance 267990
7 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His)SNV Uncertain significance 335760 rs143981573 2:31562482-31562482 2:31339616-31339616
8 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu)SNV Uncertain significance 598996 rs1558697792 2:31602803-31602803 2:31379937-31379937

Expression for Neutropenia

Search GEO for disease gene expression data for Neutropenia.

Pathways for Neutropenia

GO Terms for Neutropenia

Biological processes related to Neutropenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.67 IL3 CSF3R CSF3 CSF2
2 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.5 IL3 HAX1 CSF3
3 positive regulation of actin cytoskeleton reorganization GO:2000251 9.4 HAX1 CSF3
4 regulation of myeloid cell differentiation GO:0045637 9.26 CSF3R CSF2
5 neutrophil migration GO:1990266 9.16 JAGN1 CD177
6 glucose-6-phosphate transport